These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 29478795)

  • 41. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma.
    Brown DB; Fundakowski CE; Lisker-Melman M; Crippin JS; Pilgram TK; Chapman W; Darcy MD
    J Vasc Interv Radiol; 2004 Nov; 15(11):1209-18. PubMed ID: 15525739
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of the Interval between Transarterial Chemoembolization Sessions on Survival in Patients with Unresectable Hepatocellular Carcinoma.
    Kim HD; An J; Kim JH; Gwon DI; Shin JH; Ko GY; Yoon HK; Sung KB; Kim KM; Lee HC
    J Vasc Interv Radiol; 2016 Apr; 27(4):504-13. PubMed ID: 26896049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile.
    Odisio BC; Ashton A; Yan Y; Wei W; Kaseb A; Wallace MJ; Vauthey JN; Gupta S; Tam AL
    J Vasc Interv Radiol; 2015 Jul; 26(7):965-71. PubMed ID: 25979305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies.
    Savic LJ; Chapiro J; Funai E; Bousabarah K; Schobert IT; Isufi E; Geschwind JH; Stark S; He P; Rudek MA; Perez Lozada JC; Ayyagari R; Pollak J; Schlachter T
    Eur Radiol; 2021 May; 31(5):3002-3014. PubMed ID: 33063185
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma.
    Boulin M; Ciboulet A; Guiu B; Maillard E; Bonnetain F; Minello A; Gagnaire A; Lepage C; Krause D; Hillon P; Bedenne L; Cercueil JP; Chauffert B; Jouve JL
    Dig Liver Dis; 2011 Nov; 43(11):905-11. PubMed ID: 21802381
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy.
    Miki I; Murata S; Uchiyama F; Yasui D; Ueda T; Sugihara F; Saito H; Yamaguchi H; Murakami R; Kawamoto C; Uchida E; Kumita SI
    World J Gastroenterol; 2017 Sep; 23(35):6437-6447. PubMed ID: 29085193
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Liver Resection versus Radiofrequency Ablation plus Transcatheter Arterial Chemoembolization in Cirrhotic Patients with Solitary Large Hepatocellular Carcinoma.
    Saviano A; Iezzi R; Giuliante F; Salvatore L; Mele C; Posa A; Ardito F; De Gaetano AM; Pompili M;
    J Vasc Interv Radiol; 2017 Nov; 28(11):1512-1519. PubMed ID: 28734848
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score-Matched Study.
    Padia SA; Johnson GE; Horton KJ; Ingraham CR; Kogut MJ; Kwan S; Vaidya S; Monsky WL; Park JO; Bhattacharya R; Hippe DS; Harris WP
    J Vasc Interv Radiol; 2017 Jun; 28(6):777-785.e1. PubMed ID: 28365172
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma.
    Facciorusso A; Mariani L; Sposito C; Spreafico C; Bongini M; Morosi C; Cascella T; Marchianò A; Camerini T; Bhoori S; Brunero F; Barone M; Mazzaferro V
    J Gastroenterol Hepatol; 2016 Mar; 31(3):645-53. PubMed ID: 26331807
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).
    Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
    J Surg Oncol; 2010 May; 101(6):476-80. PubMed ID: 20213741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center.
    Aliberti C; Carandina R; Lonardi S; Dadduzio V; Vitale A; Gringeri E; Zanus G; Cillo U
    J Vasc Interv Radiol; 2017 Nov; 28(11):1495-1502. PubMed ID: 28927662
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
    Matsumoto T; Ichikawa H; Imai J; Hayashi T; Tomita K; Mine T; Kojima S; Watanabe N; Hasebe T
    Anticancer Res; 2017 Jun; 37(6):3183-3187. PubMed ID: 28551662
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.
    Pinter M; Ulbrich G; Sieghart W; Kölblinger C; Reiberger T; Li S; Ferlitsch A; Müller C; Lammer J; Peck-Radosavljevic M
    Radiology; 2015 Dec; 277(3):903-12. PubMed ID: 26131911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review.
    Horikawa M; Miyayama S; Irie T; Kaji T; Arai Y
    AJR Am J Roentgenol; 2015 Oct; 205(4):764-73. PubMed ID: 26397324
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Triple-drug transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: assessment of survival in 124 consecutive patients.
    Gomes AS; Rosove MH; Rosen PJ; Amado RG; Sayre JW; Monteleone PA; Busuttil RW
    AJR Am J Roentgenol; 2009 Dec; 193(6):1665-71. PubMed ID: 19933662
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis.
    Pietrosi G; Miraglia R; Luca A; Vizzini GB; Fili' D; Riccardo V; D'Antoni A; Petridis I; Maruzzelli L; Biondo D; Gridelli B
    J Vasc Interv Radiol; 2009 Jul; 20(7):896-902. PubMed ID: 19497762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study.
    Yang H; Seon J; Sung PS; Oh JS; Lee HL; Jang B; Chun HJ; Jang JW; Bae SH; Choi JY; Yoon SK
    J Vasc Interv Radiol; 2017 Nov; 28(11):1503-1511.e2. PubMed ID: 28941589
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
    Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
    Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.